PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
About
The overarching goal of this notice of funding opportunity (NOFO) and its companion opportunities is to establish the Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Program to support development of innovative, reliable, cost-effective, and sustainable multimodal AI-based clinical decision support (CDS) tools. PRIMED-AI CDS tools are based on the integration of clinical imaging with other types of multimodal health data to enhance care for patients with a wide range of health conditions. The PRIMED-AI Program seeks to catalyze the adoption of AI-based CDS tools into clinical workflows to enable novel personalized medicine strategies that address significant health challenges. The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze the development and testing of Artificial Intelligence (AI)-enabled, image-centered, multimodal Clinical Decision Support (CDS) tools, developed in pursuance as Software as a Medical Device (SaMD). These projects are expected to have high potential for demonstrable, positive impact on patient outcomes and/or healthcare processes.
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) is a federal funding opportunity designed for organizations developing innovative AI-enabled clinical decision support (CDS) tools that integrate medical imaging with multimodal health data. This program is ideal for academic institutions, healthcare organizations, technology companies, and research teams committed to advancing precision medicine through artificial intelligence. The grant supports the development and testing of Software as a Medical Device (SaMD) solutions that enhance patient outcomes and improve healthcare processes across a wide range of health conditions. Entrepreneurs and innovators should apply if they have expertise in AI, medical imaging, clinical data integration, and healthcare technology implementation. The program emphasizes creating reliable, cost-effective, and sustainable CDS tools that can be adopted into real-world clinical workflows. This is a unique opportunity to secure federal funding while building partnerships between academic researchers and industry partners, accelerating the translation of AI innovations into clinical practice. The program welcomes domestic and international collaborations, making it accessible to global organizations with U.S. partners. Success requires demonstrating high potential for positive impact on patient outcomes and establishing a clear pathway to clinical adoption.
Funding Facts
● Applications openDeadline
October 19, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by project scope and mechanism (refer to NOFO for details)
Deadline
2026-10-19
Grant Type
federal
Application Cycle
Annual with deadline October 19, 2026
Best For
Academic institutions, healthcare organizations, technology companies, and academic-industrial partnerships developing AI-based clinical decision support tools using imaging and multimodal data integration
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Frequently Asked Questions
Who is eligible for PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)?
Eligible applicants include academic institutions, healthcare organizations, industry partners, and research teams developing AI-based clinical decision support tools. Both domestic (U.S.) and non-domestic (international) organizations may apply. Non-domestic components of U.S. organizations and foreign collaborators are eligible as defined in NIH policy. For complete eligibility requirements, including organizational type, funding history, and partnership requirements, refer to Section III of the official Notice of Funding Opportunity (NOFO) on the NIH website.
How much funding does PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional) provide?
Specific funding amounts are not provided in current available information. Funding levels may vary depending on project scope, the UG3/UH3 mechanism selected, and whether a clinical trial is included. Consult the official NOFO on the NIH grants website for detailed budget information, funding caps, and guidance on budget justification for your specific project type.
How do I apply for PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)?
Applications are submitted through the NIH electronic submission system (eRA Commons/ASSIST). Applicants should prepare a detailed project narrative describing their AI-enabled CDS tool, imaging integration strategy, multimodal data approach, and clinical implementation plan. The application deadline is October 19, 2026. Visit the official NIH NOFO webpage for complete application instructions, required forms, submission guidelines, and technical assistance resources.
What can PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional) funding be used for?
Funding supports the development and testing of AI-enabled, image-centered clinical decision support tools developed as Software as a Medical Device (SaMD). Projects should focus on integrating clinical imaging with other multimodal health data to enhance patient care and support personalized medicine strategies. The UG3/UH3 mechanism allows phased approaches, with optional clinical trial components. Funding may support research personnel, technology development, data integration, validation studies, and activities demonstrating clinical adoption potential.
Last updated: July 5, 2026